31 December 2012
Are hepatitis C-positive allografts in simultaneous pancreas-kidney transplantation underutilized?
Jorge OrtizABCDEF, John GunselmanBE, Imran JavedAE, Stalin CamposAE, Kamran KhanmoradiAE, Radi ZakiAEDOI: 10.12659/AOT.883692
Ann Transplant 2012; 17(4): 39-44
Abstract
Background: A recent review reported that recipient HCV infection had no significant impact on acute rejection rates or patient survival in SPKT but the utilization of HCV(+) organs was negligible. Using the UNOS database, we sought to determine utilization rates for HCV(+) allografts in Simultaneous Pancreas-Kidney Transplantation (SPKT.
Material/Methods: The Organ Procurement and Transplant Network / United Network for Organ Sharing database was employed to obtain information regarding HCV(+) and HCV-negative (HCV(–)) SPKT recipients and the disposition of donor pancreata.
Results: Between 2000 and January 2011, 702 of 25,904 donors (2.7%) were HCV(+) and met otherwise ideal criteria. We identified 16 patients who received HCV(+) organs for SPKT between 1995 and 2010. Four had kidney allograft losses secondary to chronic rejection. Six had pancreatic allograft losses: one due to pancreatitis, one to infection, one to chronic rejection, one to acute rejection and two to graft thrombosis. None of the sixteen patients were subsequently listed for liver transplantation. Meanwhile, 702 HCV(+) donors between the age of 14 and 40 with a BMI less than 30 were identified. During that time period, only 8 simultaneous pancreas-kidney transplants using HCV(+) donor organs occurred. Therefore, 694 HCV(+) pancreata were not utilized for SPKT in that time span.
Conclusions: 16 patients have undergone SPKT with HCV(+) organs. Aggressive use of HCV(+) organs for SPKT could potentially lead to earlier transplantation for HCV(+) recipients and allow HCV(–) organs to be available more quickly for HCV(-) recipients additional research of this topic is warranted.
Keywords: hepatitis C, kidney, pancreas, transplant, Hepatitis C, Kidney, Pancreas, transplant
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






